CDTX:NSD-Cidara Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.56

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Volume

0.70M

Avg Analyst Target

USD 7.13 (+356.73%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD131.81B 38.58 31.39
BNTX BioNTech SE

N/A

USD67.50B 15.50 10.94
REGN Regeneron Pharmaceuticals Inc

N/A

USD61.22B 10.34 7.53
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.54B 24.20 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD35.36B N/A N/A
SGEN Seagen Inc

N/A

USD31.19B 53.49 43.63
GMAB Genmab A/S

N/A

USD30.33B 78.11 8.55
ALNY Alnylam Pharmaceuticals Inc

N/A

USD23.60B N/A N/A
RPRX Royalty Pharma plc

N/A

USD22.77B 30.36 12.47

ETFs Containing CDTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.00% 47% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.00% 47% F 21% F
Trailing 12 Months  
Capital Gain -48.51% 18% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.51% 18% F 7% F
Trailing 5 Years  
Capital Gain -84.63% 20% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.63% 20% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -16.11% 13% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.11% 13% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 53.72% 58% F 33% F
Risk Adjusted Return -29.98% 18% F 8% F
Market Capitalization 0.10B 22% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.96 24% F 20% F
Price / Cash Flow Ratio -1.91 16% F 57% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -163.97% 14% F 14% F
Return on Invested Capital -219.26% 5% F 3% F
Return on Assets -42.40% 17% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.39 69% D+ 58% F
Short Percent 1.40% 83% B 68% D+
Beta 1.33 50% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector